OTCMKTS:VYYRF Voyageur Pharmaceuticals (VYYRF) Stock Price, News & Analysis $0.10 0.00 (0.00%) As of 06/23/2026 03:39 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartBuy This Stock About Voyageur Pharmaceuticals Stock (OTCMKTS:VYYRF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get VYYRF alerts:Sign Up Key Stats Today's Range$0.10▼$0.1050-Day Range$0.01▼$0.1052-Week Range$0.00▼$0.24Volume20,000 shsAverage Volume16,638 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Voyageur Pharmaceuticals, Inc. is a biopharmaceutical company specializing in advanced drug-delivery technologies and contract development services. The company focuses on formulating and optimizing therapeutic compounds to enhance stability, bioavailability and controlled-release properties. By leveraging proprietary polymer- and lipid-based delivery platforms, Voyageur aims to partner with pharmaceutical and biotechnology firms to address formulation challenges in high-value therapeutic areas, including oncology, endocrinology and central nervous system disorders. The company’s core offerings include formulation development, analytical testing, preclinical evaluation and small-scale manufacturing support. Through these services, Voyageur helps clients advance candidate molecules from early-stage proof-of-concept to IND-enabling studies, de-risking programs and shortening development timelines. Its technical capabilities encompass nano-and micro-particle engineering, sterile injectable systems, oral controlled-release formulations and other specialized dosage forms designed to improve patient compliance and therapeutic outcomes. Voyageur Pharmaceuticals is headquartered in the United States and serves a global customer base of emerging biotech firms and established pharmaceutical companies. The company’s collaborative approach combines internal R&D expertise with strategic external partnerships to tailor delivery solutions for novel and legacy drug candidates. Led by a management team with extensive experience in pharmaceutical development and regulatory affairs, Voyageur continues to expand its platform capabilities and position itself as a contract development organization of choice for challenging drug-delivery projects.AI Generated. May Contain Errors. Read More Receive VYYRF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Voyageur Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VYYRF Stock News HeadlinesVoyageur Pharmaceuticals Evaluates Three U.S. Sites for Integrated Iodine and Barium Contrast Media Manufacturing FacilityJune 18, 2026 | finance.yahoo.comVYYRF Voyageur Pharmaceuticals Ltd.May 30, 2026 | seekingalpha.comTrump’s Currency Coup ExposedTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 is orchestrating what analyst Porter Stansberry calls a total U.S. money reset, bypassing conventional legal channels under the guise of national security. The last time America reset its currency - under Nixon in the 1970s - it created an average of 1,300 new millionaires a day for over 50 years. Stansberry has identified three asset categories connected to Trump's initiative that could surge, plus his single top investment move.June 26 at 1:00 AM | Porter & Company (Ad)Voyageur Announces Advancements on Its Barium & Iodine Contrast Media ProjectsMarch 16, 2026 | finance.yahoo.comVoyageur Pharmaceuticals partners with VAST on Frances Creek permitting workAugust 18, 2025 | proactiveinvestors.comVoyageur Pharmaceuticals signs LOI for Latin American distribution partnershipJune 24, 2025 | proactiveinvestors.comVoyageur Pharmaceuticals advances iodine-based pharma manufacturing strategy with Altillion collaborationJune 23, 2025 | proactiveinvestors.comVoyageur Pharmaceuticals books first commercial sale with barium contrast agents orderJune 4, 2025 | proactiveinvestors.comSee More Headlines VYYRF Stock Analysis - Frequently Asked Questions How have VYYRF shares performed this year? Voyageur Pharmaceuticals' stock was trading at $0.1301 at the beginning of the year. Since then, VYYRF shares have decreased by 23.1% and is now trading at $0.10. How do I buy shares of Voyageur Pharmaceuticals? Shares of VYYRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolOTCMKTS:VYYRF CIKN/A Webwww.voyageurminerals.ca Phone(587) 779-6166FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (OTCMKTS:VYYRF) was last updated on 6/26/2026 by MarketBeat.com Staff. From Our PartnersBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredThe EPA just put a kill switch on Elon’s empireA federal EPA permit expires January 2, 2027 - and if Elon Musk's Colossus supercomputer loses power that day,...Behind the Markets | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredSpaceX IPO “cancelled”?SpaceX is approaching what could be a $1.6 trillion IPO - potentially the largest in history. But Louis Navell...InvestorPlace | SponsoredRickards Predicts: Trump to buy tiny $2 stock?Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...Paradigm Press | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely, LLC | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Voyageur Pharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Voyageur Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.